Pharvaris (PHVS) Cash from Restructuring (2021 - 2022)
Pharvaris' (PHVS) quarterly Cash from Restructuring came in at -$115903.2 in Q4 2022, up 55.72% YoY from -$74430.1 in Q4 2021, and down 12315.94% on a QoQ basis from $948.79 in Q3 2022.
Powered by 
Analysis
Pharvaris (PHVS) Cash from Restructuring (2021 - 2022) Analysis & Trends
Pharvaris (PHVS) has 2 years of Cash from Restructuring data on file, last reported at -$115903.2 in Q4 2022.
- Quarterly Cash from Restructuring rose 55.72% year-over-year to -$115903.2 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was -$376709.8 (changed N/A YoY) and the FY2025 annual result came in at -$12.3 million, down 2023.99% from the prior year.
- Cash from Restructuring declined to -$115903.2 in Q4 2022, from $948.79 in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of $948.79 in Q3 2022 to a low of -$261755.4 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -115,903.16 |
| Sep 30, 2022 | 948.79 |
| Dec 31, 2021 | -261,755.43 |